slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 236,821-236,850
Pages 10,126
Rows per page 30
Component
236,821-236,850 of 303,780
02
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Problem1 hit
03
The slide uses a hub-and-spoke layout to connect the central brand to five key operational pillars.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Problem1 hit
04
The slide uses a combination of headshots for the team and a logo grid for both past company experience and product experience.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Problem1 hit
05
The chart uses horizontal bars to represent clinical trial phases for specific indications.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a horizontal timeline structure to map clinical trial milestones.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
07
MindMed | Investor Presentation Deck | 42 slidesMindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Solution1 hit
08
Slide uses a list-based layout to present four distinct pillars of program progress.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a matrix-like structure to contrast clinical efficacy, market opportunity, and unmet needs across two primary indications.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The slide uses a process flow diagram to connect molecular interaction to clinical outcomes.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The slide uses a structured layout to compare clinical trial designs across two primary indications.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide uses a structured list format to map specific clinical challenges to corresponding methodological solutions.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Uses a timeline-based framework to illustrate overlapping IP protections.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Solution1 hit
15
The slide uses a three-part vertical list structure to summarize clinical trial strategy.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Market Size1 hit
16
The slide uses a bar chart to visually demonstrate superiority over standard of care.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Market SizeLoop · Pattern Hunter1 hit
17
The slide uses a list-based framework to map clinical outcomes to target product profile attributes.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Market SizeLoop · Pattern Hunter1 hit
18
The slide uses a timeline-like structure to show the progression from Part A to Part B for two distinct studies.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Market SizeLoop · Pattern Hunter1 hit
19
Includes study timeline, randomization, entry criteria, and endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · ProductLoop · Pattern Hunter1 hit
20
The slide uses a process flow diagram to illustrate the study design.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · ProductLoop · Pattern Hunter1 hit
21
The slide uses a callout box to link the primary endpoint to historical Phase 2b performance data.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Product1 hit
23
The slide uses a table to establish historical and modern clinical validity for LSD therapy.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Product1 hit
24
The chart highlights statistical significance at specific time points (Week 1, 2, 4, 8, 12) using asterisks.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Product1 hit
25
The slide outlines the study structure for MM120-310, with MM120-311 design pending.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Product1 hit
26
Includes study design, randomization, primary endpoint, entry criteria, and secondary endpoints.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Product1 hit
28
The slide emphasizes regulatory alignment and standard clinical trial methodology.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations Beat · Product1 hit
29
Includes study design, dosing arms, primary/secondary endpoints, and entry criteria.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
30
The slide uses a table to contrast what is included in the patient journey versus what is explicitly excluded (no preparation, no assisted therapy, no integration).MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
31
The slide uses a process flow diagram to track patient retention from randomization through 12 weeks.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
32
The table shows n=194 total participants across 5 cohorts. HAM-A and CGI-S are standard clinical scales for anxiety and severity of illness.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
33
The chart highlights the 100ug dose group performance relative to placebo and other doses.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit
34
Data shows a clear dose-response relationship peaking at 100ug.MindMed | Investor Presentation Deck | 42 slides · MindMed
Pitch deck Investor relations 1 hit